Nom du produit:ethyl 2-bromo-2,2-difluoroacetate
IUPAC Name:ethyl 2-bromo-2,2-difluoroacetate
- CAS：667-27-6
- Formule moléculaire：C4H5BrF2O2
- Pureté：95%+
- Numéro de catalogue：CM112382
- Poids moléculaire：202.98
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:667-27-6
- Formule moléculaire:C4H5BrF2O2
- Point de fusion:-
- Code SMILES:O=C(OCC)C(F)(Br)F
- Densité:
- Numéro de catalogue:CM112382
- Poids moléculaire:202.98
- Point d'ébullition:
- N° Mdl:MFCD00042069
- Stockage:
Category Infos
- Fluorinated Compounds
- Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.
Column Infos
- Carbonyl Compounds
- In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
- Fluorinated compounds
- Fluorinated compounds refers to organic or inorganic compounds containing fluorine.
- TAK-861
- Takeda announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1 and intends to rapidly initiate the first global Phase 3 trials of TAK-861 in first half of fiscal year 2024.
Recherche 
+86 21 5895 0110 
